Biologics for Psoriasis

Dermatol Clin. 2024 Jul;42(3):339-355. doi: 10.1016/j.det.2024.02.001. Epub 2024 Mar 13.

Abstract

Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.

Keywords: Biologics; Efficacy; Psoriasis; Safety.

Publication types

  • Review

MeSH terms

  • Adalimumab / therapeutic use
  • Antibodies, Monoclonal* / therapeutic use
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Biological Products* / therapeutic use
  • Certolizumab Pegol / therapeutic use
  • Dermatologic Agents / therapeutic use
  • Etanercept / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Interleukin-12 / antagonists & inhibitors
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-23 / antagonists & inhibitors
  • Psoriasis* / drug therapy
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Ustekinumab* / therapeutic use

Substances

  • Biological Products
  • Ustekinumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • guselkumab
  • risankizumab
  • Tumor Necrosis Factor-alpha
  • tildrakizumab
  • secukinumab
  • Etanercept
  • ixekizumab
  • brodalumab
  • Adalimumab
  • Infliximab
  • Interleukin-17
  • Dermatologic Agents
  • Certolizumab Pegol
  • Interleukin-23
  • Interleukin-12